Work

Abstract PS2-13-08: Neoadjuvant Dalpiciclib Plus Letrozole Versus Standard Chemotherapy in High-Risk HR+/HER2- Negative Breast Cancer (DARLING-02): A Randomized Phase II Trial

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps2-13-08

Authors: C. Geng, L. Zhang, C. Yang, T. Zhou, L. Ma, R. Luo, Z. Song, Y. Qi, J. Yang, X. Wang, J. Han, J. Ma, Z. Zhang, Y. Li, C. Gao, L. Yang, J. Yu

Institutions: Hebei Medical University, Fourth Hospital of Hebei Medical University, The No. 2 People's Hospital of Lanzhou, Affiliated Hospital of Hebei University, Hebei University, Hebei University of Engineering, Tangshan People's Hospital, Hebei North University, Baoding No.1 Central Hospital, Xingtai People's Hospital

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7130749617

Cites:

Cited by:

Related to: